^
Association details:
Biomarker:PIK3CA amplification
Cancer:Lung Cancer
Drug Class:PI3K inhibitor +
EZH2 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition

Published date:
10/13/2021
Excerpt:
In this study, we observed that the PIK3CA-mutant or amplified lung cancer cells were more sensitive to EZH2 inhibition....EZH2 inhibitor synergized with PI3K inhibitor in human cancer cells in vitro and worked together efficiently in vivo....This study suggests a promising combination therapy to combat lung cancers with PIK3CA mutation or amplification.
DOI:
10.1016/j.canlet.2021.10.010